Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis

BACKGROUND: Psoriasis is a chronic inflammatory skin disease, affecting about 0.6% of the Chinese population. Many patients are not well controlled by conventional treatments, thus there is need for new treatment regimens. In this study, we assessed the efficacy and safety of secukinumab in Chinese...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Chin Med J (Engl)
Hlavní autoři: Cai, Lin, Zhang, Jian-Zhong, Yao, Xu, Gu, Jun, Liu, Quan-Zhong, Zheng, Min, Zhang, Shi-Fa, Xu, Jin-Hua, Li, Cheng-Xin, Cheng, Hao, Guo, Qing, Pan, Wei-Li, Li, Shen-Qiu, Li, Ruo-Yu, Guo, Zai-Pei, Song, Zhi-Qi, Li, Shan-Shan, Dong, Xiu-Qin, Wang, Linda, Fu, Rong, Regnault, Pascaline, Charef, Pascal, Mazur, Rafal, Patekar, Manmath
Médium: Artigo
Jazyk:Inglês
Vydáno: Lippincott Williams & Wilkins 2020
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7647502/
https://ncbi.nlm.nih.gov/pubmed/33060370
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CM9.0000000000001163
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky